Zenith Health Care Limited has submitted its quarterly regulatory declaration under Regulation 74(5) of the Depositories and Participants Regulations 2018 for the quarter ended March 31, 2026. The pharmaceutical company filed the mandatory compliance document with BSE on April 11, 2026.

Regulatory Filing Details

The company submitted the declaration through its Company Secretary and Compliance Officer, Mihir S Shah (Membership No: A41922). The filing was made under reference number ZHL/LIST/BSE/LODR/REG-74(5)/03-2026 and addressed to the Listing Compliance Department of BSE Limited.

RTA Certificate Confirmation

The submission included a certificate from Bigshare Services Private Limited, the company's Registrar and Share Transfer Agent (SEBI Registration Number INR000001385). The certificate, dated April 6, 2026, and issued under reference number BSS/74(5), confirms the company's compliance with dematerialization requirements.

Bigshare Services confirmed that securities received from depository participants for dematerialization up to March 31, 2026, were properly processed and confirmed to the depositories. The RTA also verified that all security certificates received for dematerialization were mutilated and cancelled after due verification by depository participants.

Compliance Framework

The declaration ensures compliance with multiple regulatory frameworks, including NSDL circular NSDL/CIR/II/5/2019 dated January 25, 2019, and CDSL circular DSL/OPS/RTA/POLICY/2019/14 dated January 25, 2019. The filing also references SEBI letter MRD/DOP2/DSA2/OW/2019/2498/1 dated January 24, 2019.

Operational Infrastructure

Zenith Healthcare Limited operates from its registered office at 504, Iscon Elegance, Near Ananddham Jain Derasar, Prahladnagar Cross Road, S.G. Road, Ahmedabad-380015. The company maintains manufacturing units at Changodar Industrial Estate and Bhat, Ahmedabad, along with a dedicated godown facility. The WHO-cGMP and ISO 9001:2008 certified company continues to maintain proper connectivity with both NSDL and CDSL depositories through its registered transfer agent.

Zenith Healthcare Limited has announced its unaudited financial results for the third quarter of FY26, demonstrating a significant turnaround in its financial performance. The pharmaceutical company's Board of Directors approved the quarterly results at a meeting held on February 12, 2026, showing marked improvement across key financial metrics.

Financial Performance Highlights

The company reported strong financial recovery in Q3FY26, with several key metrics showing substantial improvement over the previous year.

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, Zenith Healthcare maintained its positive trajectory with consistent performance improvements.

Operational Efficiency Improvements

The company's operational metrics reflect improved cost management and efficiency. Cost of materials consumed decreased significantly to ₹83.13 lakh in Q3FY26 from ₹114.36 lakh in Q3FY25, representing a substantial reduction of 27.33%. Employee benefits expense increased to ₹52.28 lakh from ₹49.96 lakh, while other expenses rose to ₹86.37 lakh from ₹82.06 lakh in the corresponding previous quarter.

Corporate Governance and Compliance

The financial results were reviewed and approved by the Board of Directors, with statutory auditors Doshi Doshi & Co conducting a limited review of the quarterly results. The results comply with Indian Accounting Standards and SEBI Listing Obligations and Disclosure Requirements Regulations 2015. The company maintains a single reportable segment in pharmaceuticals trading as per Ind AS 108 requirements.

Capital Structure Details

Zenith Healthcare's paid-up equity share capital remains stable at ₹537.39 lakh with a face value of ₹1 per share. The company's earnings per share showed significant improvement, moving from negative ₹0.05 in Q3FY25 to positive ₹0.042 in Q3FY26, reflecting the strong operational turnaround and improved profitability metrics.